๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT ยท Real-Time Price ยท USD
2.430
+0.070 (2.97%)
At close: Nov 18, 2026, 4:00 PM EST
2.400
-0.030 (-1.23%)
After-hours: Nov 18, 2026, 7:58 PM EST

Nautilus Biotechnology Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue was $200,000 and net loss was $15.6M; cash runway is projected into Q1 2028. The roadmap targets Voyager pre-orders in early 2027, shipments in mid-2027, and 20 assays by mid-2028.

  • R&D focus has shifted to proteoform applications due to strong customer demand and technical progress, with first revenue recognized this quarter. Operating expenses declined, cash runway extends into 2028, and commercial ramp is expected as new assays and platform launches approach.

  • AGM 2026

    The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its frequency. All proposals passed, with annual Say on Pay votes approved. No questions were submitted during the Q&A session.

  • Q1 2026 saw strong execution on commercialization plans, reduced operating expenses, and expanded early access engagement, with Baylor College of Medicine as a key customer. Cash runway extends through 2027, and oncology assay development is on track for later this year.

  • Proteomics remains a critical bottleneck in drug development, with current technologies lacking depth and reproducibility. A new platform leveraging iterative mapping and advanced software aims to transform protein analysis, with early applications in Alzheimer's and oncology, and a strong financial runway supporting commercialization through 2027.

  • A novel proteomics platform was showcased, offering unprecedented sensitivity and reproducibility for both broadscale and targeted protein analysis. Early access programs are underway, with commercial launch and expanded assay portfolio expected by next year.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022